Welcome to our dedicated page for Orgenesis news (Ticker: ORGS), a resource for investors and traders seeking the latest updates and insights on Orgenesis stock.
Orgenesis Inc (ORGS) is a global biotechnology leader pioneering decentralized cell and gene therapy manufacturing. This page provides investors and industry professionals with centralized access to official press releases, clinical trial updates, and strategic partnership announcements.
Track the latest developments in ORGS's innovative platforms, including therapeutic exosome production, automated GMP processes, and modular cleanroom deployments. Our curated news collection ensures timely updates on regulatory milestones, research breakthroughs, and operational expansions.
Key coverage areas: clinical trial progress, manufacturing partnerships, technology licensing agreements, and regulatory submissions. Bookmark this page for direct access to verified information about ORGS's advancements in immuno-oncology and regenerative medicine.
Orgenesis Inc. (NASDAQ: ORGS) reported a remarkable increase in POCare revenues, surging to $10.5 million for Q2 2021, a more than six-fold rise from $1.75 million in Q2 2020. This growth is attributed to enhanced technology transfer and expansion of partnerships within its POCare network. The company aims to address industry bottlenecks in cell and gene therapy production by offering a decentralized supply model. Orgenesis continues adding advanced clinical trials and expanding its global partnerships, including collaborations with notable healthcare institutions like Johns Hopkins University.
On August 3, 2021, Orgenesis Inc (NASDAQ: ORGS) announced a conference call scheduled for August 5, 2021, at 8:30 AM ET to discuss corporate progress and developments. Interested parties can join via telephone or access a webcast. A replay will be available on the company’s Investor Events section until August 5, 2022. Orgenesis is a biotech firm focused on cell and gene therapies, utilizing its POCare Platform to enhance the accessibility and affordability of these therapies globally.
Orgenesis (NASDAQ: ORGS) announced it completed a pre-IND consultation with the FDA for its phase 2 trial of Ranpirnase for anogenital warts. The company confirmed it is on schedule for the submission. Additionally, its partner Okogen reported positive interim results from a phase 2 trial of OKG-0301 (Ranpirnase) in acute adenoviral conjunctivitis. Orgenesis is also collaborating with Leidos for a clinical trial of Ranpirnase against SARS-CoV-2. The company is exploring reformulating Ranpirnase with Bioxome technology, enhancing its delivery and manufacturing scalability.
Orgenesis (NASDAQ: ORGS) has started enrollment for a phase 2, randomized, placebo-controlled trial evaluating the safety and efficacy of autologous stromal and vascular fraction (SVF) injections after rotator cuff surgery. The trial is being conducted at the Hospital for Special Surgery in New York, using the Tissue Genesis Icellator, with 56 patients expected to be enrolled. Early evidence suggests SVF may enhance tissue regeneration and mitigate inflammation. The investigator Dr. Scott Rodeo expresses optimism about the trial's potential to improve patient outcomes.
Orgenesis, a global biotech company focused on cell and gene therapies, announced its participation in the Summer Solstice Conference hosted by The MicroCap Rodeo, from June 1-4, 2021. CEO Vered Caplan will present on June 2 at 2:30 PM Eastern Time and engage in one-on-one meetings with investors. The conference showcases the top 25 companies recommended as best ideas by qualified institutional investors. Interested parties can access the presentation live or on replay through the provided link.
Orgenesis Inc. (NASDAQ: ORGS) reported a more than four-fold revenue increase for Q1 2021, attributed to long-term contracts with regional partners under its new POCare strategy. The company achieved positive operating income and maintained a robust cash position of $41.8 million as of March 31, 2021. Orgenesis is advancing therapeutic pipelines with over 30 advanced cell and gene therapies, focusing on autologous immunotherapies and metabolic diseases. The company continues to expand its POCare Network globally, collaborating with hospitals and investing in new point-of-care technologies.
Orgenesis (NASDAQ: ORGS) has received Investigational Device Exemption (IDE) approval from the FDA for a first-in-human feasibility study of the Tissue Genesis Icellator2® to treat Acute Respiratory Distress Syndrome (ARDS) related to COVID-19. The trial will involve 21 patients at one site in the U.S. and aims to evaluate the therapeutic efficacy of stromal and vascular cells (SVF) derived from adipose tissue. The company may also amend its development plan to address non-COVID-19 related ARDS. This milestone reflects significant progress in Orgenesis's clinical development strategy.
Orgenesis (NASDAQ: ORGS) announced a conference call to discuss corporate progress on May 7, 2021, at 8:30 AM ET. Analysts and investors can join the call via telephone or webcast. The call will be accessible again as a replay on the Investor Events section of their website. Orgenesis aims to enhance cell and gene therapies through its POCare Platform, which promotes affordable and accessible treatments. This platform includes licensed therapeutics and focuses on decentralized production at the point of care, collaborating with various stakeholders worldwide.
Orgenesis (NASDAQ: ORGS) has announced its collaboration with Bambino Gesù Children's Hospital in Rome to establish a Point of Care Cell Therapy center. This center will support clinical trials and the development of advanced cell and gene therapies, aiming to streamline manufacturing processes and reduce costs. The partnership also allows for the deployment of Orgenesis' Mobile Processing Units (OMPULs) on-site, enhancing decentralized production capabilities. This collaboration marks a significant step for Orgenesis in expanding its POCare Network globally.
Orgenesis has announced a strategic collaboration with MIDA Biotech to establish point-of-care centers across Italy, Germany, Spain, and Benelux. This partnership aims to deploy Orgenesis Mobile Processing Units and Labs (OMPULs) for the onsite development of cell and gene therapies. The collaboration highlights Orgenesis' commitment to expanding its POCare Network and providing scalable, affordable access to therapies. The agreements signify crucial steps towards commercialization, as hospitals have conducted thorough due diligence before engaging.
FAQ
What is the current stock price of Orgenesis (ORGS)?
What is the market cap of Orgenesis (ORGS)?
